Potential liver-related side effects have led to the FDA placing a partial clinical hold on a MacroGenics-developed bispecific antibody for cancer.

Axovant has halted development of nelotanserin after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia.

Luma Therapeutics launched its UV-based plaque psoriasis device, available through a dermatologist or Luma’s telehealth provider, HealthLens.

Merck KGaA has licensed a cloud-based artificial intelligence proteome screening platform from the Toronto-based Cyclica.

Eisai and University College London are moving their first candidate into the clinic: a tau-targeting monoclonal antibody for Alzheimer’s disease.

Xenotransplantation firm eGenesis hires new R&D head; Relay adds execs to chemistry, R&D; and Navidea brings on new CMO focused on imaging.

A team of Stanford University scientists has found a way to direct a regenerative diabetes medicine to the right cells more precisely.

The offering gives DiaMedica the cash to take its lead candidate through phase 2 trials in acute ischemic stroke and chronic kidney disease.

Moderna’s much-anticipated IPO has come in even larger than expected at $604 million, valuing the company at an eye-watering $7.9 billion.